activation of the glp-1 receptor signalling pathway a relevant strategy to repair a deficient beta-cell massglp-1受体信号通路的激活相关策略缺乏β细胞修复质量.pdfVIP

Hindawi Publishing Corporation Experimental Diabetes Research Volume 2011, Article ID 376509, 11 pages doi:10.1155/2011/376509 Review Article Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass ´ Bernard Portha, Cecile Tourrel-Cuzin, and Jamileh Movassat Laboratoire B2PE (Biologie et Pathologie du Pancr´eas Endocrine), Unit´e BFA (Biologie Fonctionnelle et Adaptive), Equipe 1, Universit´e Paris-Diderot et CNRS EAC 4413, Bˆatiment BUFFON, 5`eme etage,´ pi`ece 552A, 4, Rue Lagroua Weill Hall´e, Case 7126, 75205 Paris Cedex 13, France Correspondence should be addressed to Bernard Portha, portha@univ-paris-diderot.fr Received 30 December 2010; Accepted 25 February 2011 Academic Editor: Matteo Monami Copyright © 2011 Bernard Portha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for